论文部分内容阅读
目的研究重组人脑利钠肽治疗缺血性心肌病伴急性心力衰竭的临床疗效。方法选取安新县医院2012—2013年收治的符合“急性心力衰竭诊断标准”的缺血性心肌病伴急性心力衰竭的患者108例,随机分成观察组和对照组,每组54例。两组患者在入院后均采取常规方法治疗,观察组患者在上述基础上联合应用重组人脑利钠肽治疗,7d为1个疗程。比较两组患者的临床疗效及治疗后的收缩压(SBP)、舒张压(DBP)、左心室射血分数(LVEF)、左室舒张末内径(LVED)、左房舒张末内径(LAED)。结果观察组总有效率为96.29%,高于对照组的88.89%,差异有统计学意义(P<0.05)。治疗后两组患者SBP、DBP、LVEF、LVED、LAED比较,差异有统计学意义(P<0.05)。结论重组人脑利钠肽治疗缺血性心肌病伴急性心力衰竭的疗效显著,能较好地提高患者的生活质量。
Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of ischemic cardiomyopathy with acute heart failure. Methods A total of 108 patients with ischemic cardiomyopathy and acute heart failure who met the diagnostic criteria of acute heart failure admitted to Anxin Hospital from 2012 to 2013 were randomly divided into observation group and control group with 54 cases in each group. Both groups were treated by conventional method after admission. The patients in the observation group were treated with recombinant human brain natriuretic peptide on the basis of the above, and 7 days was a course of treatment. The clinical efficacy and SBP, DBP, LVEF, LVED and LAED were compared between the two groups. Results The total effective rate in observation group was 96.29%, which was higher than that in control group (88.89%), the difference was statistically significant (P <0.05). The difference of SBP, DBP, LVEF, LVED and LAED between the two groups after treatment was statistically significant (P <0.05). Conclusion The therapeutic effect of recombinant human brain natriuretic peptide in the treatment of ischemic cardiomyopathy with acute heart failure is significant, which can better improve the quality of life of patients.